Investigational Medication Sirolimus for Lymphangioleiomyomatosis (LAM)

Trial Objective

Investigational Medication Sirolimus for Lymphangioleiomyomatosis (LAM)The purpose of this study is to see if a drug called sirolimus slows development of lymphangioleiomyomatosis (LAM), a lung disease in which abnormal cells growing inside the lungs prevent them from working properly.

Sirolimus is approved by the United States Food and Drug Administration (FDA) for the treatment of LAM. A recent trial showed that sirolimus stabilized lung function in patients with moderate and severe disease. Our researchers want to find out if giving low-dose sirolimus earlier in the course of treatment safely and effectively prevents further lung damage from LAM.


New enrollment for this trial is temporarily paused

Who Can Participate

Adults who have been diagnosed with lymphangioleiomyomatosis are eligible to participate. 

Age: 18+    Gender: Any Gender

Estimated Time Commitment

2 years

The study will last for two years and involve seven visits and one phone call, as well as a remote blood draw. Total time commitment is about 9 hours.

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Jami Henriksen, Trial Coordinator

Jami Henriksen

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

National Institutes of Health (NIH)

Principal Investigators

Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at